Market: NASD |
Currency: USD
Address: 15440 Laguna Canyon Road
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Show more
📈 Tarsus Pharmaceuticals, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$76.25
-
Upside/Downside from Analyst Target:
29.57%
-
Broker Call:
14
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
25-50%
-
Net Income Growth Range (1Y):
25-50%
-
Revenue Growth Range (1Y):
200-500%
-
Upcoming Earnings Date:
2025-11-11
-
EPS Estimate:
-0.35
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Tarsus Pharmaceuticals, Inc.
| Date | Reported EPS |
|---|
| 2025-11-10 (estimated upcoming) | - |
| 2025-08-06 | -0.48 |
| 2025-05-01 | -0.64 |
| 2025-02-25 | -0.6 |
| 2024-11-13 | -0.61 |
| 2024-08-08 | -0.83 |
| 2024-05-08 | -0.99 |
| 2024-02-27 | -1.31 |
| 2023-11-09 | -1.27 |
| 2023-08-10 | -1.17 |
| 2023-05-09 | -0.87 |
| 2023-03-13 | -0.5 |
| 2022-11-09 | -0.84 |
| 2022-08-11 | -0.22 |
| 2022-05-10 | -0.96 |
| 2022-03-14 | -0.57 |
| 2021-11-09 | -0.76 |
| 2021-08-04 | 0.33 |
| 2021-05-11 | 0.47 |
| 2021-03-31 | -0.56 |
| 2020-11-25 | -0.5 |
📰 Related News & Research
No related articles found for "tarsus pharmaceuticals".
